Elsevier

Clinical Therapeutics

Volume 31, Issue 1, January 2009, Pages 1-31
Clinical Therapeutics

Drug treatment of paraphilic and nonparaphilic sexual disorders

https://doi.org/10.1016/j.clinthera.2009.01.009Get rights and content

Abstract

Background: Paraphilias are characterized by recurrent, intense, sexually arousing fantasies, urges, or behaviors, over a period of ≥6 months, generally involving nonhuman objects, suffering or humiliation of oneself or one's partner, or children or other noncon-senting persons. These fantasies, urges, and behaviors produce clinically significant distress or impairments in social, occupational, and other important areas of functioning.

Objective: The goal of this article was to provide an in-depth review of the clinical pharmacology of the main antiandrogens (cyproterone acetate, medroxyprogesterone acetate [MPA], and the luteinizing hormone-releasing hormone [LHRH] agonists) used in the treatment of the paraphilias, as well as a discussion of the relevant clinical case reports, case series, and controlled trials. Treatment recommendations are also provided.

Methods: Relevant publications were identified through a search of the English-language literature indexed on MEDLINE/PubMed (1966-September 2008) using the search terms paraphilia, sex offender, hypersexuality, sexual behaviors, fetish, transvestic fetishism, sexual addiction, sexual compulsivism, selective serotonin reuptake inhibitors, tricyclic antidepressants, antiandrogens, cyproterone acetate, medroxyprogesterone acetate, LHRH agonists, and estrogens. Additional publications were identified from the bibliographies of retrieved publications.

Results: In vitro and in vivo (animal) studies have revealed that serotonin and prolactin inhibit sexual arousal, while norepinephrine (via α1-adrenoceptor activation), dopamine, acetylcholine (via muscarinic receptor activation), enkephalins, oxytocin, gonadotropin-releasing hormone, follicle-stimulating hormone, luteinizing hormone, testosterone/dihydrotestosterone, and estrogen/progesterone stimulate it. Most of the currently used pharmacologic treatments of the paraphilias have serotonin and testosterone/dihydrotestosterone as their targets. Cognitive-behavioral psychotherapy should be initiated in all offenders. In those at the highest risk of reoffending, psychotherapy should be initiated at the same time as drug therapy because their combination is associated with better results compared with either as monotherapy (especially in pedophiles). In offenders committing non-“hands-on” or violent paraphilias and those at low risk of reoffending, serotoninergic monotherapies (selective serotonin reuptake inhibitors [SSRIs] or tricyclic antidepressants) are reasonable choices (SSRIs are preferred). In other offenders, initial dual combination therapy (serotoninergic plus antiandrogenic) is recommended. Progestogens should be used before LHRH agonists or estrogens. Cyproterone acetate and MPA are preferred as oral and IM progestogens, respectively. Failure of dual combination serotoninergic/ progestogen therapy should prompt a change in one or both of the components (eg, SSRI to tricyclic antidepressants or vice versa, or cyproterone acetate to MPA or vice versa) or the addition or substitution of an LHRH agonist (leuprolide or triptorelin) for the progestogen. Estrogens are second- or third-line agents. Rarely, triple combination therapy is necessary (serotoninergic plus LHRH agonist or progestogen plus estrogen). It appears that recidivism rates are reduced by the use of psychotherapy alone, drug therapy alone, and more so by their combination.

Conclusions: Although some progress has been made in the therapy of paraphilic and nonparaphilic sexual disorders, much work remains to be done. The development of more specific, more effective, and better-tolerated medications for these disorders should be recognized as a program worthy of greater support from government and pharmaceutical industry sources. Clinical studies performed to date have largely been of poor design, making the recommendations provided in this review tentative at best.

References (170)

  • JM Schober et al.

    The neurophysiology of sexual arousal

    Best Pract Res Clin Endocrinol Metab

    (2007)
  • H Gordon

    The treatment of paraphilias: An historical perspective

    Crim Behav Ment Health

    (2008)
  • JR Hughes

    Review of medical reports on pedophilia

    Clin Pediatr (Phila)

    (2007)
  • LE Weinberger et al.

    The impact of surgical castration on sexual recidivism risk among sexually violent predatory offenders

    J Am Acad Psychiatry Law

    (2005)
  • C Durhng

    Never going home: Does it make it safer? Does it make sense? Sex offenders, residency restrictions, and reforming risk management law

    J Crim Law Criminol

    (2006)
  • T Kenworthy et al.

    Psychological interventions for those who have sexually offended or are at risk of offending

    Cochrane Database Syst Rev

    (2004)
  • JA Keeling et al.

    Comparing sexual offender treatment efficacy: Mainstream sexual offenders and sexual offenders with special needs

    J Intellect Dev Disabil

    (2007)
  • AR Torres et al.

    Exhibitionism treated with clomipramine

    Am J Psychiatry

    (1993)
  • C Casals-Anet et al.

    Exhibitionism treated with clomipramine

    Am J Psychiatry

    (1993)
  • FE Wawrose et al.

    Clomipramine and a case of exhibitionism

    Am J Psychiatry

    (1992)
  • MP Kafka

    Successful treatment of paraphihc coercive disorder (a rapist) with fluoxetine hydrochloride

    Br J Psychiatry

    (1991)
  • RD Perilstein et al.

    Three cases of paraphilias responsive to fluoxetine treatment

    J Clin Psychiatry

    (1991)
  • LS Lorefice

    Fluoxetine treatment of a fetish

    J Clin Psychiatry

    (1991)
  • J Kerbeshian et al.

    Tourette syndrome and recurrent paraphihc masturbatory fantasy

    Can J Psychiatry

    (1991)
  • VT Jorgensen

    Cross-dressing successfully treated with fluoxetine

    NY State J Med

    (1990)
  • VB Galli et al.

    An adolescent male with multiple paraphilias successfully treated with fluoxetine

    J Child Adolesc Psychopharmacol

    (1998)
  • MD Bianchi

    Fluoxetine treatment of exhibitionism

    Am J Psychiatry

    (1990)
  • NP Emmanuel et al.

    Fluoxetine treatment of voyeurism

    Am J Psychiatry

    (1991)
  • R Langevin et al.

    The effect of assertiveness training, Provera, and sex of therapist in the treatment of genital exhibitionism

    J Behav Ther Exp Psychiatry

    (1979)
  • JM Bradford et al.

    A treatment for impulse control disorders and paraphilia: A case report

    Can J Psychiatry

    (1995)
  • L Warneke

    Phenelzine and sexuality

    J Clin Psychiatry

    (1994)
  • M Coskun et al.

    Mirtazapine treatment in a subject with autistic disorder and fetishism

    J Child Adolesc Psychopharmacol

    (2008)
  • IS Shiah et al.

    Treatment of paraphilic sexual disorder: The use of topiramate in fetishism

    Int Clin Psychopharmacol

    (2006)
  • RL Goldberg et al.

    The use of carbamazepine for the treatment of paraphilias in a brain damaged patient

    Int J Psychiatry Med

    (1982–1983)
  • D Varela et al.

    Pedophilia treated with carbamazepine and clonazepam

    Am J Psychiatry

    (2002)
  • JP Fedoroff

    Buspirone hydrochloride in the treatment of transvestic fetishism

    J Clin Psychiatry

    (1988)
  • JP Fedoroff

    Buspirone hydrochloride in the treatment of an atypical paraphilia

    Arch Sex Behav

    (1992)
  • NG Ward

    Successful lithium treatment of transvestism associated with manic-depression

    J Nerv Ment Dis

    (1975)
  • JA Cesnik et al.

    Use of lithium carbonate in the treatment of autoerotic asphyxia

    Am J Psychother

    (1989)
  • P Buckley et al.

    Role of serotonin in forensic psychiatry

    Bull Am Acad Psychiatry Law

    (1996)
  • R Sandyk

    Naltrexone suppresses abnormal sexual behavior in Tourette's syndrome

    Int J Neurosa

    (1988)
  • FM Volpe et al.

    Cyproterone for hypersexuality in a psychotic patient with Wilson's disease

    Aust NZJ Psychiatry

    (2000)
  • J Zbytovský et al.

    Cyproteronacetate in the therapy of sexual deviations

    Act Nerv Super (Praha)

    (1979)
  • CS Mellor et al.

    Female hypersexuality treated with cyproterone acetate

    Am J Psychiatry

    (1988)
  • AJ Cooper et al.

    Antiandrogen (cyproterone acetate) therapy in deviant hypersexuality

    Br J Psychiatry

    (1972)
  • AJ Cooper et al.

    The long-term use of cyproterone acetate in pedophilia: A case study

    J Sex Marital Ther

    (1992)
  • KR Britton

    Medroxyprogesterone in the treatment of aggressive hypersexual behavior in traumatic brain injury

    Brain Inj

    (1998)
  • AJ Cooper et al.

    Medroxyprogesterone acetate, nocturnal penile tumescence, laboratory arousal, and sexual acting out in a male with schizophrenia

    Arch Sex Behav

    (1990)
  • SL Moore

    Satyriasis: A case study

    J Clin Psychiatry

    (1980)
  • OA Cordoba et al.

    Medroxyprogesterone acetate antiandrogen treatment of hypersexuality in a pedophihac sex offender

    Am J Psychiatry

    (1983)
  • Cited by (91)

    • Self-Medication of Paraphilic Ideation Contributing to a Pulmonary Embolism: A Case Report

      2021, Journal of the Academy of Consultation-Liaison Psychiatry
      Citation Excerpt :

      Progesterone compounds are recommended before use of estrogens or luteinizing hormone–releasing hormone agonists. The most used include cyproterone acetate as an oral preparation and medroxyprogesterone acetate as an intramuscular injection.10 Estrogens are considered second- or third-line treatments owing to the risk of thrombogenesis.

    • Behavioral dyscontrol

      2020, Brain Injury Medicine: Board Review
    • Zoophilia and hypersexuality in an adult male with schizophrenia: A case report

      2019, Neurology Psychiatry and Brain Research
      Citation Excerpt :

      Various pharmacological as well as non-pharmacological strategies have been tried for the treatment of paraphilias. The pharmacological agents basically target hormonal receptors (oxytocin, prolactin, testosterone, estrogens, leuteinizing hormones, follicular stimulating hormone) or serotonin-dopamine-norepinephrine receptors (Guay, 2009). Unprotected sexual contact with animals increases the risk of acquiring sexually transmitted diseases and rare zoonotic diseases, which can be further transmitted to other individuals in the society through sexual contact.

    • The Concept of “Hypersexuality” in the Boundary between Physiological and Pathological Sexuality

      2023, International Journal of Environmental Research and Public Health
    View all citing articles on Scopus
    View full text